Selank

The earlier profile gives Selank as Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue peptide. Its research history does not establish a clinical outcome. Manufacturing identity needs the complete sequence and an explicit statement of the terminal form.

The older resin discussion refers to amide-forming supports without consistently separating terminal-form specifications. That ambiguity is not resolved here by choosing a form. The inherited tables remain examples requiring confirmation against the actual product specification.

The described route uses Fmoc (a temporary chemical protecting group) solid-phase peptide synthesis, with protected side chains and coupling checks as the chain is assembled. Proline-rich segments call for appropriate monitoring of reaction completion; the process record needs evidence rather than an assumption based on sequence length.

Cleavage and deprotection produce a crude mixture for analysis. The earlier process discussion covers activation reagents, resin behaviour and crude characterisation. Those are linked variables in development, not a transferable production recipe.

RP-HPLC (reversed-phase high-performance liquid chromatography, which separates mixture components) separates the intended chain from deletion sequences and other related material. Analytical review determines which fractions can be combined. The old preparative settings and recovery figures are retained as unverified examples.

Counterion exchange is particularly relevant to interpreting weighed material with basic side chains. Water and associated salts add mass without becoming peptide. Freeze-drying and final isolation therefore need both physical checks and a measured content result.

The earlier identity panel combines mass, composition and chromatographic evidence. Purity measures the detected impurity profile; content measures peptide relative to the whole sample. Those results should appear separately on a certificate.

Impurity profiling, residual-solvent analysis, water and microbiological methods complete different parts of release testing. Every claimed result needs a method reference, qualified standard where relevant, and the actual batch identifier.

The earlier stability account considers hydrolysis, oxidation, aggregation and possible cyclisation. Those are proposed pathways to investigate with methods that can distinguish target from changed material. Light and temperature stress are part of study design.

Storage and shipping records should refer to data for the actual powder and container. Powder stability is not evidence of the stability of every laboratory solution.

The batch record connects material qualification, synthesis, purification, drying and quality review. Digital certificates need traceable source data and controlled signatures. Process design, qualification and continued monitoring remain separate stages during scale-up and technology transfer.

FDA’s page current as of April 22, 2026 lists selank among substances nominated but withdrawn. Withdrawal does not mean clearance or approval. Its public Oath listing establishes a catalogue entry, not drug status or suitability of a particular lot.

Selank tables retain the earlier manufacturing examples. No Selank table here validates an operating procedure, release limit or supplier result. The Selank examples have no supporting batch raw data; use them to identify document fields, not to infer measured performance.

Selank source links are retained below. These references give context for Selank manufacturing; they do not validate the numerical examples. Duplicate Selank source links retain the citation record.

1. 1
2. 2
3. 3
4. 4
5. 5
6. 6
7. 7
8. 8
9. 9
10. 10
11. 11
12. 12
13. 13
14. 14
15. Coin I, Beyermann M, Bienert M. "Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences." Nature Protocols. 2007;2(12):3247-3256. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315689/
16. Amblard M, Fehrentz JA, Martinez J, Subra G. "Methods and protocols of modern solid phase peptide synthesis." Molecular Biotechnology. 2006;33(3):239-254. Available at: https://www.sciencedirect.com/science/article/pii/S0040402013012345
17. Albericio F. "Developments in peptide and amide synthesis." Current Opinion in Chemical Biology. 2004;8(3):211-221. Available at: https://pubs.acs.org/doi/10.1021/cr040410z
18. Fekete S, Guillarme D, Dong MW. "Chromatographic and mass spectrometric strategies for peptide bioanalysis and purification." Chromatography Today. 2019. Available at: https://www.chromatographytoday.com/news/hplc-uhplc/31/breaking-news/peptide-purification-strategies-for-pharmaceutical-manufacturing/58923
19. Patel SM, Doen T, Pikal MJ. "Determination of end point of primary drying in freeze-drying process control." American Pharmaceutical Review. 2010. Available at: https://www.americanpharmaceuticalreview.com/Featured-Articles/188841-Lyophilization-Process-Development-and-Optimization/
20. International Council for Harmonisation (ICH). "ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology." 2005. Available at: https://www.ich.org/page/quality-guidelines
21. United States Pharmacopeia (USP). "General Chapter <1065>: Ion Chromatography." Available at: https://www.usp.org/harmonization-standards/pdg
22. U.S. Food and Drug Administration. "Current Good Manufacturing Practice (CGMP) Regulations." 21 CFR Parts 210, 211. Available at: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
23. U.S. Food and Drug Administration. "Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production." 2006. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigating-out-specification-oos-test-results-pharmaceuticals
24. International Council for Harmonisation (ICH). "Q1A(R2): Stability Testing of New Drug Substances and Products." 2003. Available at: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
25. United States Pharmacopeia (USP). "General Chapter <1079>: Good Storage and Distribution Practices for Drug Products." Available at: https://www.usp.org/harmonization-standards/pdg/general-chapters/storage-distribution
26. U.S. Food and Drug Administration. "Guidance for Industry: Part 11, Electronic Records; Electronic Signatures — Scope and Application." 2003. Available at: https://www.fda.gov/media/71001/download
27. U.S. Food and Drug Administration. "Process Validation: General Principles and Practices." 2011. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices
28. U.S. Food and Drug Administration. "Guide to Inspections Validation of Cleaning Processes (7/93)." Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/guide-inspections-validation-cleaning-processes-7937